Gilead Sciences to amass Repare’s RP-3467
Gilead Sciences has signed an settlement to amass Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.
The transaction entails a complete consideration of as much as $30m to Repare and straight influences the corporate’s money standing and upcoming shareholder preparations.
Uncover B2B Advertising That Performs
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
In accordance with the phrases, Gilead can pay Repare $25m upfront, topic to customary holdbacks and changes, and as much as an extra $5m upon completion of sure know-how switch actions.
On 14 November 2025, Repare introduced a definitive association settlement with XenoTherapeutics and Xeno Acquisition. Below this settlement, Xeno agreed to buy all of Repare’s issued and excellent widespread shares.
The amount of money every shareholder will obtain per share can be based mostly on Repare’s closing money stability, after subtracting transaction-related bills and excellent liabilities.
The upfront fee from the Polθ ATPase inhibitor acquisition has elevated Repare’s money reserves, thereby elevating the estimate for shareholder funds.
Primarily based on the revised money stability, Repare estimates shareholders will obtain about $2.20 per widespread share upon closing the association transaction.
Repare Therapeutics president, CEO and chief monetary officer Steve Forte mentioned: “We’re happy to announce this transaction which mixes Gilead’s main experience in oncology analysis and growth with RP-3467, a possible best-in-class Polθ ATPase inhibitor. This marks the third and most important portfolio transaction for Repare this 12 months.”
RP-3467 is a potent small molecule inhibitor of Polθ, an artificial lethality goal linked to breast most cancers gene (BRCA) mutations and different genomic alterations.
In Could 2025, Repare entered an out-licensing settlement with Canadian biotechnology agency DCx Biotherapeutics for discovery platforms and mental property (IP).
Join our day by day information round-up!
Give your corporation an edge with our main business insights.
